Interest of tumor-specific CD4 T helper 1 cells for therapeutic anticancer vaccine

Vaccines

Volumn 3, Issue 3, 2015, Pages 490-502

  Galaine, Jeanne ^a,b,c   Borg, Christophe ^a,b,c,d   Godet, Yann ^a,b,c   Adotévi, Olivier ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Cancer vaccine; CD4 T cell; Helper peptide; Tumor antigen

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; CD40 LIGAND; CXCL9 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; IPILIMUMAB; KEYHOLE LIMPET HEMOCYANIN; NIVOLUMAB; PEMBROLIZUMAB; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; MISSENSE MUTATION; REVIEW;

EID: 85016913953     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3030490     Document Type: Review

References (103)

1. Sharma, P.; Allison, J.P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015, 161, 205-214.
2. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252-264.
3. Chen, D.S.; Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013, 39, 1-10.
4. Butterfield, L.H. Cancer vaccines. Br. Med. J. 2015, doi:10.1136/bmj.h988.
5. Ajewski, T.F.; Meng, Y.; Harlin, H. Immune suppression in the tumor microenvironment. J. Immunother. 2006, 29, 233-240.
6. Hunder, N.N.; Wallen, H.; Cao, J.; Hendricks, D.W.; Reilly, J.Z.; Rodmyre, R.; Jungbluth, A.; Gnjatic, S.; Thompson, J.A.; Yee, C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 2008, 358, 2698-2703.
7. Tran, E.; Turcotte, S.; Gros, A.; Robbins, P.F.; Lu, Y.C.; Dudley, M.E.; Wunderlich, J.R.; Somerville, R.P.; Hogan, K.; Hinrichs, C.S.; et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344, 641-645.
8. Slingluff, C.L.; Lee, S.; Zhao, F.; Chianese-Bullock, K.A.; Olson, W.C.; Butterfield, L.H.; Whiteside, T.L.; Leming, P.D.; Kirkwood, J.M. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin. Cancer Res. 2013, 19, 4228-4238.
9. Reed, C.M.; Cresce, N.D.; Mauldin, I.S.; Slingluff, C.L.; Olson, W.C. Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival. Clin. Cancer Res. 2015, doi:10.1158/1078-0432.CCR-15-0233.
10. Kreiter, S.; Vormehr, M.; van de Roemer, N.; Diken, M.; Löwer, M.; Diekmann, J.; Boegel, S.; Schrörs, B.; Vascotto, F.; Castle, J.C.; et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015, 520, 692-696.
11. Zanetti, M. Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics. J. Immunol. 2015, 194, 2049-2056.
12. Mosmann, T.R.; Coffman, R.L. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989, 7, 145-173.
13. Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005, 6, 345-352.
14. Korn, T.; Oukka, M.; Kuchroo, V.; Bettelli, E. Th17 cells: Effector T cells with inflammatory properties. Semin. Immunol. 2007, 19, 362-371.
15. Végran, F.; Apetoh, L.; Ghiringhelli, F. Th9 cells: A novel CD4 T-cell subset in the immune war against cancer. Cancer Res. 2015, 75, 475-479.
16. Trifari, S.; Kaplan, C.D.; Tran, E.H.; Crellin, N.K.; Spits, H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells. Nat. Immunol. 2009, 10, 864-871.
17. Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 2011, 29, 621-663.
18. Geginat, J.; Paroni, M.; Maglie, S.; Alfen, J.S.; Kastirr, I.; Gruarin, P.; de Simone, M.; Pagani, M.; Abrignani, S. Plasticity of human CD4 T cell subsets. Front. Immunol. 2014, doi:10.3389/fimmu.2014.00630.
19. Zhu, J.; Paul, W.E. CD4 T cells: Fates, functions, and faults. Blood 2008, 112, 1557-1569.
20. Kennedy, R.; Celis, E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 2008, 222, 129-144.
21. Kim, H.J.; Cantor, H. CD4 T-cell subsets and tumor immunity: The helpful and the not-so-helpful. Cancer Immunol. Res. 2014, 2, 91-98.
22. Pardoll, D.M.; Topalian, S.L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 1998, 10, 588-594.
23. Ridge, J.P.; di Rosa, F.; Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393, 474-478.
24. Bennett, S.R.; Carbone, F.R.; Karamalis, F.; Flavell, R.A.; Miller, J.F.; Heath, W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393, 478-480.
25. Smith, C.M.; Wilson, N.S.; Waithman, J.; Villadangos, J.A.; Carbone, F.R.; Heath, W.R.; Belz, G.T. Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity. Nat. Immunol. 2004, 5, 1143-1148.
26. Wong, S.B.J.; Bos, R.; Sherman, L.A. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J. Immunol. 2008, 180, 3122-3131.
27. Bos, R.; Sherman, L.A. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010, 70, 8368-8377.
28. Dosset, M.; Godet, Y.; Vauchy, C.; Beziaud, L.; Lone, Y.C.; Sedlik, C.; Liard, C.; Levionnois, E.; Clerc, B.; Sandoval, F.; et al. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin. Cancer Res. 2012, 18, 6284-6295.
29. Dosset, M.; Vauchy, C.; Beziaud, L.; Adotevi, O.; Godet, Y. Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. Oncoimmunology 2013, doi:10.4161/onci.23430.
30. Nakanishi, Y.; Lu, B.; Gerard, C.; Iwasaki, A. CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature 2009, 462, 510-513.
31. Ikeda, H.; Old, L.J.; Schreiber, R.D. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13, 95-109.
32. Xie, Y.; Akpinarli, A.; Maris, C.; Hipkiss, E.L.; Lane, M.; Kwon, E.K.M.; Muranski, P.; Restifo, N.P.; Antony, P.A. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 2010, 207, 651-667.
33. Quezada, S.A.; Simpson, T.R.; Peggs, K.S.; Merghoub, T.; Vider, J.; Fan, X.; Blasberg, R.; Yagita, H.; Muranski, P.; Antony, P.A.; et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010, 207, 637-650.
34. Matsuzaki, J.; Tsuji, T.; Luescher, I.; Old, L.J.; Shrikant, P.; Gnjatic, S.; Odunsi, K. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4+ T Cells. Cancer Immunol. Res. 2014, 2, 341-350.
35. Ayyoub, M.; Pignon, P.; Classe, J.-M.; Odunsi, K.; Valmori, D. CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg. Cancer Immunol. Res. 2013, 1, 303-308.
36. Campi, G.; Crosti, M.; Consogno, G.; Facchinetti, V.; Conti-Fine, B.M.; Longhi, R.; Casorati, G.; Dellabona, P.; Protti, M.P. CD4+ T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res. 2003, 63, 8481-8486.
37. Godet, Y.; Fabre, E.; Dosset, M.; Lamuraglia, M.; Levionnois, E.; Ravel, P.; Benhamouda, N.; Cazes, A.; le Pimpec-Barthes, F.; Gaugler, B.; et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: Potential synergistic effect with chemotherapy response. Clin. Cancer Res. 2012, 18, 2943-2953.
38. Vauchy, C.; Gamonet, C.; Ferrand, C.; Daguindau, E.; Galaine, J.; Beziaud, L.; Chauchet, A.; Henry Dunand, C.J.; Deschamps, M.; Rohrlich, P.S.; et al. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. Int. J. Cancer 2015, 137, 116-126.
39. Wang, X.F.; Kerzerho, J.; Adotevi, O.; Nuyttens, H.; Badoual, C.; Munier, G.; Oudard, S.; Tu, S.; Tartour, E.; Maillère, B. Comprehensive analysis of HLA-DR-and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J. Immunol. 2008, 181, 431-439.
40. Kudela, P.; Sun, Z.; Fourcade, J.; Janjic, B.; Kirkwood, J.M.; Maillere, B.; Zarour, H.M. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J. Immunol. 2011, 186, 312-322.
41. Ohue, Y.; Eikawa, S.; Okazaki, N.; Mizote, Y.; Isobe, M.; Uenaka, A.; Fukuda, M.; Old, L.J.; Oka, M.; Nakayama, E. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int. J. Cancer 2012, 131, E649-E658.
42. Tsuji, T.; Matsuzaki, J.; Ritter, E.; Miliotto, A.; Ritter, G.; Odunsi, K.; Old, L.J.; Gnjatic, S. Split T cell tolerance against a self/tumor antigen: Spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. PLoS ONE 2011, 6, e23651.
43. Yoshida, N.; Abe, H.; Ohkuri, T.; Wakita, D.; Sato, M.; Noguchi, D.; Miyamoto, M.; Morikawa, T.; Kondo, S.; Ikeda, H.; et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int. J. Oncol. 2006, 28, 1089-1098.
44. Zhang, Z.; Huang, J.; Zhang, C.; Yang, H.; Qiu, H.; Li, J.; Liu, Y.; Qin, L.; Wang, L.; Hao, S.; et al. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer Gene Ther. 2015, 22, 198-206.
45. Fridman, W.H.; Dieu-Nosjean, M.C.; Pagès, F.; Cremer, I.; Damotte, D.; Sautès-Fridman, C.; Galon, J. The immune microenvironment of human tumors: General significance and clinical impact. Cancer Microenviron. 2013, 6, 117-122.
46. Fridman, W.H.; Pagès, F.; Sautès-Fridman, C.; Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 2012, 12, 298-306.
47. Fayolle, C.; Deriaud, E.; Leclerc, C. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J. Immunol. 1991, 147, 4069-4073.
48. Antony, P.A.; Piccirillo, C.A.; Akpinarli, A.; Finkelstein, S.E.; Speiss, P.J.; Surman, D.R.; Palmer, D.C.; Chan, C.C.; Klebanoff, C.A.; Overwijk, W.W.; et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174, 2591-2601.
49. Knutson, K.L.; Disis, M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 2005, 54, 721-728.
50. Cecil, D.L.; Holt, G.E.; Park, K.H.; Gad, E.; Rastetter, L.; Childs, J.; Higgins, D.; Disis, M.L. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res. 2014, 74, 2710-2718.
51. Beatty, G.L.; Vonderheide, R.H. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev. Vaccines 2008, 7, 881-887.
52. Kobayashi, H.; Wood, M.; Song, Y.; Appella, E.; Celis, E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 2000, 60, 5228-5236.
53. Piesche, M.; Hildebrandt, Y.; Zettl, F.; Chapuy, B.; Schmitz, M.; Wulf, G.; Trümper, L.; Schroers, R. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum. Immunol. 2007, 68, 572-576.
54. Jäger, E.; Jäger, D.; Karbach, J.; Chen, Y.T.; Ritter, G.; Nagata, Y.; Gnjatic, S.; Stockert, E.; Arand, M.; Old, L.J.; et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4 * 0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 2000, 191, 625-630.
55. Hiltbold, E.M.; Ciborowski, P.; Finn, O.J. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res. 1998, 58, 5066-5070.
56. Kobayashi, H.; Celis, E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr. Opin. Immunol. 2008, 20, 221-227.
57. Adotévi, O.; Dosset, M.; Galaine, J.; Beziaud, L.; Godet, Y.; Borg, C. Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Hum. Vaccines Immunother. 2013, 9, 1073-1077.
58. Del Guercio, M.F.; Alexander, J.; Kubo, R.T.; Arrhenius, T.; Maewal, A.; Appella, E.; Hoffman, S.L.; Jones, T.; Valmori, D.; Sakaguchi, K.; et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997, 15, 441-448.
59. Valmori, D.; Pessi, A.; Bianchi, E.; Corradin, G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 1992, 149, 717-721.
60. Slingluff, C.L.; Petroni, G.R.; Chianese-Bullock, K.A.; Smolkin, M.E.; Ross, M.I.; Haas, N.B.; von Mehren, M.; Grosh, W.W. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J. Clin. Oncol. 2011, 29, 2924-2932.
61. Woods, K.; Cebon, J. Tumor-specific T-cell help is associated with improved survival in melanoma. Clin. Cancer Res. 2013, 19, 4021-4023.
62. Disis, M.L.; Wallace, D.R.; Gooley, T.A.; Dang, Y.; Slota, M.; Lu, H.; Coveler, A.L.; Childs, J.S.; Higgins, D.M.; Fintak, P.A.; et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 2009, 27, 4685-4692.
63. Brunsvig, P.F.; Kyte, J.A.; Kersten, C.; Sundstrøm, S.; Møller, M.; Nyakas, M.; Hansen, G.L.; Gaudernack, G.; Aamdal, S. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin. Cancer Res. 2011, 17, 6847-6857.
64. Kyte, J.A. Cancer vaccination with telomerase peptide GV1001. Expert Opin. Investig. Drugs 2009, 18, 687-694.
65. Middleton, G.; Silcocks, P.; Cox, T.; Valle, J.; Wadsley, J.; Propper, D.; Coxon, F.; Ross, P.; Madhusudan, S.; Roques, T.; et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial. Lancet Oncol. 2014, 15, 829-840.
66. Widmann, C.; Romero, P.; Maryanski, J.L.; Corradin, G.; Valmori, D. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods 1992, 155, 95-99.
67. Shirai, M.; Pendleton, C.D.; Ahlers, J.; Takeshita, T.; Newman, M.; Berzofsky, J.A. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. 1994, 152, 549-556.
68. Hiranuma, K.; Tamaki, S.; Nishimura, Y.; Kusuki, S.; Isogawa, M.; Kim, G.; Kaito, M.; Kuribayashi, K.; Adachi, Y.; Yasutomi, Y. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 1999, 80, 187-193.
69. Bijker, M.S.; van den Eeden, S.J.F.; Franken, K.L.; Melief, C.J.M.; van der Burg, S.H.; Offringa, R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 2008, 38, 1033-1042.
70. Zeng, G.; Li, Y.; El-Gamil, M.; Sidney, J.; Sette, A.; Wang, R.; Rosenberg, S.A.; Robbins, P.F. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: A new strategy for vaccine design. Cancer Res. 2002, 62, 3630-3635.
71. Van der Burg, S.H.; Melief, C.J. Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 2011, 23, 252-257.
72. Zwaveling, S.; Mota, S.C.F.; Nouta, J.; Johnson, M.; Lipford, G.B.; Offringa, R.; Burg, S.H. van der Melief, C.J.M. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 2002, 169, 350-358.
73. Vambutas, A.; DeVoti, J.; Nouri, M.; Drijfhout, J.W.; Lipford, G.B.; Bonagura, V.R.; van der Burg, S.H.; Melief, C.J.M. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005, 23, 5271-5280.
74. Kenter, G.G.; Welters, M.J.P.; Valentijn, A.R.P.M.; Lowik, M.J.G.; Berends-van der Meer, D.M.A.; Vloon, A.P.G.; Essahsah, F.; Fathers, L.M.; Offringa, R.; Drijfhout, J.W.; et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361, 1838-1847.
75. Disis, M.L.; Gooley, T.A.; Rinn, K.; Davis, D.; Piepkorn, M.; Cheever, M.A.; Knutson, K.L.; Schiffman, K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 2002, 20, 2624-2632.
76. Aarntzen, E.H.J.G.; de Vries, I.J.M.; Lesterhuis, W.J.; Schuurhuis, D.; Jacobs, J.F.M.; Bol, K.; Schreibelt, G.; Mus, R.; de Wilt, J.H.W.; Haanen, J.B.A.G.; et al. Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013, 73, 19-29.
77. Wierecky, J.; Müller, M.R.; Wirths, S.; Halder-Oehler, E.; Dörfel, D.; Schmidt, S.M.; Häntschel, M.; Brugger, W.; Schröder, S.; Horger, M.S.; et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006, 66, 5910-5918.
78. Inderberg-Suso, E.M.; Trachsel, S.; Lislerud, K.; Rasmussen, A.M.; Gaudernack, G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. OncoImmunology 2012, 1, 670-686.
79. Hu, Y.; Petroni, G.R.; Olson, W.C.; Czarkowski, A.; Smolkin, M.E.; Grosh, W.W.; Chianese-Bullock, K.A.; Slingluff, C.L. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol. Immunother. 2014, 63, 779-786.
80. Protti, M.P.; Monte, L.D.; Lullo, G.D. Tumor antigen-specific CD4+ T cells in cancer immunity: From antigen identification to tumor prognosis and development of therapeutic strategies. Tissue Antigens 2014, 83, 237-246.
81. Simon, T.; Fonteneau, J.F.; Grégoire, M. Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy. Immunotherapy 2013, 5, 565-567.
82. Grabowska, A.K.; Kaufmann, A.M.; Riemer, A.B. Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design. Int. J. Cancer 2015, 136, 212-224.
83. Andersen, R.S.; Thrue, C.A.; Junker, N.; Lyngaa, R.; Donia, M.; Ellebæk, E.; Svane, I.M.; Schumacher, T.N.; Thor Straten, P.; Hadrup, S.R. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 2012, 72, 1642-1650.
84. Benlalam, H.; Labarrière, N.; Linard, B.; Derré, L.; Diez, E.; Pandolfino, M.C.; Bonneville, M.; Jotereau, F. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): Implications for immunotherapy. Eur. J. Immunol. 2001, 31, 2007-2015.
85. Lennerz, V.; Fatho, M.; Gentilini, C.; Frye, R.A.; Lifke, A.; Ferel, D.; Wölfel, C.; Huber, C.; Wölfel, T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl. Acad. Sci. USA 2005, 102, 16013-16018.
86. Danan-Gotthold, M.; Golan-Gerstl, R.; Eisenberg, E.; Meir, K.; Karni, R.; Levanon, E.Y. Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Res. 2015, doi:10.1093/nar/gkv210.
87. Guilloux, Y.; Lucas, S.; Brichard, V.G.; Van Pel, A.; Viret, C.; de Plaen, E.; Brasseur, F.; Lethé, B.; Jotereau, F.; Boon, T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyl transferase V gene. J. Exp. Med. 1996, 183, 1173-1183.
88. Nehrt, N.L.; Peterson, T.A.; Park, D.; Kann, M.G. Domain landscapes of somatic mutations in cancer. BMC Genomics 2012, doi:10.1186/1471-2164-13-S4-S9.
89. Yadav, M.; Jhunjhunwala, S.; Phung, Q.T.; Lupardus, P.; Tanguay, J.; Bumbaca, S.; Franci, C.; Cheung, T.K.; Fritsche, J.; Weinschenk, T.; et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515, 572-576.
90. Linnemann, C.; van Buuren, M.M.; Bies, L.; Verdegaal, E.M.E.; Schotte, R.; Calis, J.J.A.; Behjati, S.; Velds, A.; Hilkmann, H.; Atmioui, D.E.; et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 2015, 21, 81-85.
91. Schumacher, T.N.; Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 2015, 348, 69-74.
92. Snyder, A.; Makarov, V.; Merghoub, T.; Yuan, J.; Zaretsky, J.M.; Desrichard, A.; Walsh, L.A.; Postow, M.A.; Wong, P.; Ho, T.S.; et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371, 2189-2199.
93. Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T.S.; et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348, 124-128.
94. Paul, S.; Lindestam Arlehamn, C.S.; Scriba, T.J.; Dillon, M.B.C.; Oseroff, C.; Hinz, D.; McKinney, D.M.; Carrasco Pro, S.; Sidney, J.; Peters, B.; et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J. Immunol. Methods 2015, doi:10.1016/j.jim.2015.03.022.
95. Ding, L.; Ellis, M.J.; Li, S.; Larson, D.E.; Chen, K.; Wallis, J.W.; Harris, C.C.; McLellan, M.D.; Fulton, R.S.; Fulton, L.L.; et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464, 999-1005.
96. Marusyk, A.; Almendro, V.; Polyak, K. Intra-tumour heterogeneity: A looking glass for cancer? Nat. Rev. Cancer 2012, 12, 323-334.
97. Linette, G.P.; Stadtmauer, E.A.; Maus, M.V.; Rapoport, A.P.; Levine, B.L.; Emery, L.; Litzky, L.; Bagg, A.; Carreno, B.M.; Cimino, P.J.; et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122, 863-871.
98. Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.M.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515, 568-571.
99. Walter, S.; Weinschenk, T.; Stenzl, A.; Zdrojowy, R.; Pluzanska, A.; Szczylik, C.; Staehler, M.; Brugger, W.; Dietrich, P.Y.; Mendrzyk, R.; et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, 18, 1254-1261.
100. Apetoh, L.; Ladoire, S.; Coukos, G.; Ghiringhelli, F. Combining immunotherapy and anticancer agents: The right path to achieve cancer cure? Ann. Oncol. 2015, doi:10.1093/annonc/mdv209.
101. Farsaci, B.; Donahue, R.N.; Coplin, M.A.; Grenga, I.; Lepone, L.M.; Molinolo, A.A.; Hodge, J.W. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol. Res. 2014, 2, 1090-1102.
102. Gibney, G.T.; Kudchadkar, R.R.; DeConti, R.C.; Thebeau, M.S.; Czupryn, M.P.; Tetteh, L.; Eysmans, C.; Richards, A.; Schell, M.J.; Fisher, K.J.; et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin. Cancer Res. 2015, 21, 712-720.
103. Sawada, Y.; Yoshikawa, T.; Shimomura, M.; Iwama, T.; Endo, I.; Nakatsura, T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 2015, 46, 28-36.